By clearing these cells and preventing their escape from dormancy, this approach enhances the antitumor durability of CDK4/6is, reduces the residual disease burden, and fosters a tumor microenvironment less conducive to recurrence, thereby improving long-term outcomes in patients. Here, CDK4 is linked to neoplasm.